Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CN
Context Therapeutics Inc. Common Stock
CNTX
Mkt Cap
$22.4M
Volume
2.20M
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CN
CNTX
CN
Context Therapeutics Inc. Common Stock
CNTX
News
·
New Strong Sell Stocks for October 15th
Mkt Cap
$22.4M
Volume
2.20M
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Insider
Filings
New Strong Sell Stocks for October 15th
Stock markets declined following a higher-than-expected CPI inflation report. Three companies were added to the Zacks Rank #5 (Strong Sell) list due to downward earnings estimate revisions: Cadiz Inc., Cerenome Inc., and Context Therapeutics Inc.
Zacks Investment Research · Oct 15, 2026
New Strong Sell Stocks for October 13th
Three companies have been added to the Zacks Rank #5 (Strong Sell) list due to significant downward revisions in earnings estimates over the past 60 days. ATS Corporation, an industrial automation company, saw a 6.7% downward revision. Cango Inc., a bitcoin mining company, experienced an 18.2% downward revision. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, faced a 15% downward revision.
Zacks Investment Research · Oct 13, 2026
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Step Pharma has appointed Dr. Karen Smith as Chief Medical Officer, bringing over 25 years of pharmaceutical experience to advance their CTPS1 inhibitor dencatistat across multiple cancer and blood disorder indications.
GlobeNewswire Inc. · Oct 28, 2025
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Inc. announced the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, for CLDN6-positive gynecologic and testicular cancers. The company expects to share initial data in the first half of 2026.
GlobeNewswire Inc. · Jan 14, 2025
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.
Benzinga · Dec 26, 2024
Top 10 Small-Cap Stocks to Watch in 2025
The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.
Investing.com · Dec 20, 2024
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Here is how CareCloud, Inc. (CCLD) and Context Therapeutics Inc. (CNTX) have performed compared to their sector so far this year.
Zacks Investment Research · Jun 12, 2024
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research · May 20, 2024
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research · May 14, 2024
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76
GlobeNewswire Inc. · May 8, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CN
CNTX
Context Therapeutics Inc. Common Stock
Buy
Sell
Market
Limit
Soon
CNTX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CNTX yet.
Related Tickers
Earnings